论文部分内容阅读
Background: Bevaeizumab is a monoclonal antibody currently used for the treatment of colorectal cancer.It works by preventing the formation of new blood vessels (angiogenesis).The drug has been shown to inhibit vascular endothelial growth factor (VEGF) activity.Previous research showed positive findings in other solid tumors that had metastasized.In this study, we are investigating the response of adding bevacizumab to conventional chemotherapy for metastatic breast cancer patients.Methods: Patients with metastatic breast cancer with negative Her2/Neu over-expressive were eligible.Bevacizumab was given every 2 weeks together with docetaxel plus cisplatin.The primary end point was the overall response rate and secondary end point was progression-free survival and safety profile.Results: Twenty patients were enrolled in this study from October 2005 to October 2008.The median number of treatment cycles for this study was 12 (2-12) and the median age was 49.5.The median number of treatment cycles for this study was 10.5(2-12).Seven patients achieved complete remission (35%), 9 partial remissions (45%) and the overall response rate was 80%.Conclusion: We suggest that bevacizumab in combination with dectaxel and cisplatin is an effective treatment option for metastatic breast cancer.